Long-term follow up after antithyroid drug treatment in graves'disease;Langzeitverlauf nach thyreostatischer therapie bei basedow-hyperthyreose

Praxis

Volumn 95, Issue 29-30, 2006, Pages 1121-1127

  Wille, T ^a   Muller B ^a   Noth, D ^a   Burgi U ^a   Diem, P ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

Antithyroid drugs; Graves' disease; Long term results; Thyrotropin receptor antibodies (TRAb)

Indexed keywords

EID: 33746494991     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: 10.1024/0369-8394.95.29.1121     Document Type: Article

References (33)

1. Weetman AP. Graves' disease. N Engl J Med 2000; 343: 1236-48.
2. Furszyfer J, Kurland LT, McConahay WM, Elveback LR. Graves' disease in Olmsted County, Minnesota, 1935 through 1967. Mayo Clin Proc 1970; 45: 636-44.
3. Morgensen EF, Green A. The epidemiology of thyrotoxicosis in Denmark. Incidence and geographical variation in the Funen region 1972-74. Acta Med Scand 1980; 208: 183-6. (Pubitemid 10011053)
4. Reinwein D, Benker G, König MP, Pinchera A, Schatz H, Schleusener H. Clinical aspects of hyperthyroidism in areas of different supplies of iodine. Results of a European prospective study. Schweiz Med Wochensch 1987; 117: 1245-1255. (Pubitemid 17128443)
5. Berglund J, Christensen SB, Hallengren B. Total and agespecific incidence of Graves' thyrotoxicosis, toxic nodular goiter and solitary toxic adenoma in Malmö 19 70-74. J Intern Med 1990; 227: 137-41. (Pubitemid 20038885)
6. Fajfr R, Müller B. Besondere Manifestationsformen der Autoimmunthyreopathie. Schweiz Rundsch Med Prax 2002; 1991: 1151-60.
7. Martin A, Goldsmith NK, Friedman EW, Schwartz AE, Davies TF, Roman SH. Intrathyroidal accumulation of T cell phenotypes in autoimmune thyroid disease. Autoimmunity 1990; 6: 269-81. (Pubitemid 20254081)
8. Martin A, Schwartz AE, Friedman EW, Davies TF. Successful production of intrathyroidal human T cell hybridomas: evidence of intact helper T cell function in Graves' disease. J Clin Endocrinol Metab 1989; 69: 1104-8. (Pubitemid 20010033)
9. Bottazzo GF, Pujol-Borrell R, Hanafusa T, Feldmann M. Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity. Lancet 1983; 2: 1115-9.
10. Heufelder AE. Pathogenesis of Graves' ophthalmopathy: recent controversies and progress. Eur J Endocrinol 1995; 132: 532-41.
11. Peacey SR, Flemming L, Messenger A, Weetman AP. Is Graves' dermopathy a generalized disorder? Thyroid 1996; 6: 41-5. (Pubitemid 26086068)
12. Müller B, Bürgi U. Akropachie bei Hyperthyreose. Schweiz Med Wochensch 1999; 129: 1560. (Pubitemid 29507743)
13. Maugendre D, Gatel A, Campion L et al. Antithyroid drugs and Graves' diesease - prospective randomised assessment of long-term treament. Clin Endocrinol (Oxf) 1999; 50: 127-32. (Pubitemid 29079378)
14. Weetman AP, Pickerill AP, Watson P, Chatterjee VK, Edwards OM. Treatment of Graves' disease with the block-replacement regimen with antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse. QJMed 1994; 87: 337-41. (Pubitemid 24188336)
15. Lucas A, Salinas I, Rius F et al. Medical therapy of Graves' disease: Does thyroxine prevent recurrence of hyperthyroidism? J Clin Endocrinol Metabol 1997; 82: 2410-3. (Pubitemid 27337848)
16. Solomon B, Glinoer D, Lagasse R, Wartofsky L. Current trends in the management of Graves' disease. J Clin Endocrinol Metabol 1990; 70: 1518-24.
17. McIver B, Rae P, Beckett G, Wilkinson E, Gold A, Toft A. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. N Engl J Med 1996; 334: 220-4. (Pubitemid 26030672)
18. Leary AC, Grealy G, Higgins TM et al. Long-term outcomes of treatment in hyperthyroidism in Ireland. Ir J Med Sci 1999; 168: 47-52. (Pubitemid 29094956)
19. Wang PW, Liu RT, Tung SC et al. Outcome of Graves' disease after antithyroid drug treatment in Taiwan. J Formos Med Assoc 1998; 97: 619-25.
20. Fischer H, Morgenthaler B, König MP. Therapieresultate bei hyperthyreoten Patienten aus dem Berner Kropfendemiegebiet. Schweiz Med Wochensch 1984; 114: 550-6. (Pubitemid 14085486)
21. Benker G, Reinwein D, Kahaly G et al. Is there a methimazol dose effect on remission rate in Graves' disease? Results from a long-term prospective study. The European Multicenter Trial Group of the Treatment of Hyperthyroidism with Antithyroid Drugs. Clin Endocrinol (Oxf) 1998; 49: 451-7.
22. Menendez Torre E, Anda Apinaniz E, Barbeira Layana JJ et al. Recurrence and prognostic factors after treatment with antithyroid agents in Graves-Basedow disease. Multicenter study in Northern Spain. Rev Clin Esp 2000; 200: 69-73.
23. Maugendre D, Massart C. Clinical value of a new TSH binding inhibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay. Clin Endocrinol (Oxf) 2001; 54: 89-96. (Pubitemid 32158710)
24. Mashio Y, Beniko M, Matsuda A et al. Treatment of hyperthyroidism with a small single daily dose of methimazol: a prospective long-term follow-up study. Endocrin J 1997; 44: 553-8. (Pubitemid 27406764)
25. Liu C, Duan Y, Wu X. Prospective study on the relationship between treatment duration of antithyroid drug and remission rate of Graves' disease. Zhonghua Yi Xue Za Zhi 2000; 80: 835-7.
26. Garcia-Mayor RV, Paramo C, Luna Cano R et al. Antithyroid drug and Graves' hyperthyroidism. Significance of treatment duration and TRAb determination on lasting remission. J Endcrinol Invest 1992; 15: 815-20. (Pubitemid 23060032)
27. Young ET, Steel NR, Taylor JJ et al. Prediction of remission after antithyroid drug treatment inm Graves' disease. Q J Med 1988; 66: 175-89.
28. Glinoer D, de Nayer P, Bex M. Effects of l-thyroxine administration, TSH-receptor antibodies and smoking on the risk of recurrence in Graves' hyperthyroidism treated with antithyroid drugs: a double-blind prospective randomized study. Eur J Endocrinol 2001; 144: 475-83. (Pubitemid 32487523)
29. Vitti P, Rago T, Chiovato L et al. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment. Thyroid 1997; 7: 369-75. (Pubitemid 27295133)
30. Michelangeli V, Poon C, Taft J et al. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs. Thyroid 1998; 8: 119-24. (Pubitemid 28103598)
31. Lavard L, Perrild H, Jacobsen BB et al. Prevalence of thyroid peroxidase, thyroglobulin and thyrotropin receptor antibodies in long-term follow-up of juvenile Graves disease. Autoimmunity 2000; 32: 167-72.
32. Winsa B, Dahlberg A, Jansson R et al. Factors influencing the outcome of thyrostatic drug therapy in Graves' disease. Acta Endocrinol (Copenh) 1990; 122: 722-8. (Pubitemid 20220418)
33. Rittmaster RS, Abbott EC, Douglas R et al. Effects of Methimazol, with or without L-thyroxine, on remission rates in Graves' disease. J Clin Enocrinol Metab 1998; 83: 814-8. (Pubitemid 28496452)